PulseAugur
EN
LIVE 21:35:40
中文(ZH) 东阳光药H股全流通获批

Dongyangguk Pharmaceutical's H-share full circulation approved, market cap triples

By PulseAugur Editorial · [1 sources] ·

Dongying Pharmaceutical's H-share full circulation has been approved by the China Securities Regulatory Commission. This allows 208 million domestic shares, representing 36.05% of the total share capital, to be converted into H-shares for listing. Following this approval, the company's tradable shares will significantly expand, increasing its market value in Hong Kong from HK$4.705 billion to HK$13.399 billion based on the closing price of the day. This expansion is expected to meet the thresholds for inclusion in Stock Connect and the Hang Seng Index. AI

RANK_REASON Company announcement regarding H-share full circulation approval and its impact on market value and index inclusion.

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Dongyangguk Pharmaceutical's H-share full circulation approved, market cap triples

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Significant
Company announcement regarding H-share full circulation approval and its impact on market value and index inclusion.
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
other
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Low
Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness
123 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Dongying Pharmaceutical H-share Full Circulation Approved

    36氪获悉，4月29日，东阳光药公告获证监会H股全流通备案，2.08亿股内资股获准转为H股上市，占总股本36.05%。本次全流通后公司可交易股份大幅扩容，按当日收盘价测算，港股市值由47.05亿港元升至133.99亿港元，达到港股通及恒生指数纳入门槛。

RELATED ENTITIES

RELATED TOPICS